IMRX

Immuneering Corp IMRX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $2.3M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-17.27M

Quarter to Jun 30

Free cash flow

$-16.53M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$171.66M total
FMR LLC
$48.43M+0.1%
BlackRock, Inc.
$21.83M+190.2%
Sanofi
$13.52M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$11.41MNew
PRICE T ROWE ASSOCIATES INC /MD/
$9.66M+5.8%
GEODE CAPITAL MANAGEMENT, LLC
$6.84M+114.9%
STATE STREET CORP
$5.00M+273.2%
DCF Advisers, LLC
$3.94M+458.5%
MARSHALL WACE, LLP
$3.65M-63.3%
Connor, Clark & Lunn Investment Management Ltd.
$3.00M+50.2%
ALETHEA CAPITAL MANAGEMENT, LLC
$2.36M+1962.1%
Summit Financial, LLC
$2.26M+20.0%
UBS Group AG
$2.24M+19.3%
Nuveen, LLC
$2.19MNew
NORTHERN TRUST CORP
$2.18M+271.4%
LEVIN CAPITAL STRATEGIES, L.P.
$2.07M+4040.0%
CITADEL ADVISORS LLC
$1.93M-13.6%
VANGUARD FIDUCIARY TRUST CO
$1.80MNew
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.79MNew
GSA CAPITAL PARTNERS LLP
$1.71M+347.3%
MILLENNIUM MANAGEMENT LLC
$1.65M-70.0%
Burkehill Global Management, LP
$1.50M0.0%
TWO SIGMA INVESTMENTS, LP
$1.44M+17.8%
MORGAN STANLEY
$1.13M-23.5%
Occam Crest Management LP
$1.13M-48.9%
See all 112 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/IMRX

Earnings Per Share

13fpro.ai/company/IMRX

Loading ratio trend…

IMRX key financials by period

Reported revenue, net income and operating margin by fiscal year, from Immuneering Corp's annual filings on SEC EDGAR.

Immuneering Corp reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2022$317.0K$-50.5M—
FY 2021$2.1M$-33.5M—
FY 2020$2.3M$-17.0M—
Source: IMRX filings on SEC EDGAR →

IMRX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Immuneering Corp (IMRX): stock profile, AI score and financials

Immuneering Corp (IMRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. IMRX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $2.3m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Immuneering Corp reports net income of $-17.3M, free cash flow of $-16.5M. Top institutional holders of IMRX by reported 13-F value include FMR, BlackRock, Sanofi, based on the most recent SEC filings. IMRX trades on the Nasdaq exchange and files with the SEC under CIK 1790340. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immuneering Corp directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1790340 →